β‐AR2 was recently demonstrated to cause EGFR TKI resistance through inactivation of LKB1 and induction of interleukin‐6 expression in NSCLC harboring EGFR activating mutation (Nilsson et al., 2017). This evidence concerns the gene STK11 and non-small cell lung carcinoma.